NASDAQ:TVGN

Tevogen Bio Q1 2026 Earnings Results & Report

Tevogen Bio logo
$5.69 -0.53 (-8.52%)
Closing price 11/17/2026 03:53 PM Eastern
Extended Trading
$5.74 +0.04 (+0.79%)
As of 07:47 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tevogen Bio beat analyst earnings expectations in its Q1 2026 results, released May 15, 2026. The company reported EPS of -$1.61 versus the -$2.64 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens

Tevogen Bio EPS Results

Actual EPS
-$1.61
Consensus EPS
-$2.64
Beat/Miss
Beat by +$1.03
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 5 quarters

Tevogen Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Tevogen Bio Q1 2026 Earnings FAQ

Tevogen Bio (NASDAQ:TVGN) reported earnings of -$1.61 per share for Q1 2026, beating the consensus estimate of -$2.64. The report was announced on Friday, May 15, 2026.

Tevogen Bio Earnings Headlines

What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
Tevogen Bio Holdings Rebrands as Tevogen Inc.
See More Tevogen Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tevogen Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tevogen Bio and other key companies, straight to your email.

About Tevogen Bio

Tevogen Bio (NASDAQ:TVGN) is a clinical-stage biotechnology company developing cell-based immunotherapies. Its ExacTcell platform uses donor-derived, antigen-specific T cells designed to recognize and attack disease-associated targets, with the goal of making therapies available without creating a custom treatment for each patient.

The company’s lead investigational candidate, TVGN 489, is a T-cell therapy being developed for COVID-19. Tevogen is also pursuing potential applications of its platform in cancer and other diseases. Its candidates remain investigational and are not approved treatments.

Founded by physician and health economist Ryan Saadi, who serves as the company’s chief executive officer, Tevogen became a publicly traded company in 2024 through a merger with Semper Paratus Acquisition Corporation. The company is based in Warren, New Jersey.

View Tevogen Bio Profile